Cara Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, CARA, Cara Therapeutics Inc, priceseries

Cara Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
10.68
Close
10.55
High
10.80
Low
10.39
Previous Close
10.70
Daily Price Gain
-0.15
YTD High
12.97
YTD High Date
Jan 4, 2022
YTD Low
9.63
YTD Low Date
Feb 24, 2022
YTD Price Change
-2.10
YTD Gain
-16.60%
52 Week High
29.65
52 Week High Date
Apr 9, 2021
52 Week Low
9.63
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-7.56
52 Week Gain
-41.74%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 3. 2017
9.76
Feb 10. 2017
15.27
27 Trading Days
56.45%
Link
LONG
Feb 24. 2017
15.03
Mar 10. 2017
16.08
10 Trading Days
6.97%
Link
LONG
Mar 22. 2017
16.09
Apr 3. 2017
18.00
8 Trading Days
11.84%
Link
LONG
Jan 19. 2018
13.00
Feb 1. 2018
14.17
9 Trading Days
9.00%
Link
LONG
Jun 4. 2018
15.54
Jun 22. 2018
16.61
14 Trading Days
6.87%
Link
LONG
Sep 7. 2018
19.93
Oct 2. 2018
22.77
17 Trading Days
14.26%
Link
LONG
Mar 11. 2019
17.13
Mar 22. 2019
18.69
9 Trading Days
9.11%
Link
LONG
Jul 9. 2019
22.00
Jul 25. 2019
23.84
12 Trading Days
8.36%
Link
LONG
Apr 2. 2020
12.70
Apr 30. 2020
14.82
19 Trading Days
16.73%
Link
LONG
Jun 17. 2020
15.84
Jul 14. 2020
17.08
18 Trading Days
7.82%
Link
LONG
Nov 6. 2020
13.95
Nov 20. 2020
15.39
10 Trading Days
10.29%
Link
LONG
Jan 12. 2021
17.10
Jan 27. 2021
18.39
10 Trading Days
7.55%
Link
LONG
Mar 30. 2021
20.59
Apr 22. 2021
27.38
16 Trading Days
32.98%
Link
LONG
Oct 26. 2021
14.19
Nov 10. 2021
17.02
11 Trading Days
19.94%
Link
Company Information
Stock Symbol
CARA
Exchange
NasdaqGM
Company URL
http://www.caratherapeutics.com
Company Phone
203-406-3700
CEO
Derek T. Chalmers
Headquarters
Connecticut
Business Address
4 STAMFORD PLAZA, 107 ELM STREET 9TH FLOOR, STAMFORD, CT 06902
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001346830
About

CARA Therapeutics, Inc. is a clinical-stage company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frédérique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Description

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. It is developing product candidates that target the body's peripheral nervous system. The company's lead product candidate comprises I.V. CR845, which is in Phase III clinical trials for the treatment of patients with acute postoperative pain in adult patients, as well as in Phase II/III clinical trial for the treatment of uremic pruritus disease. It is also developing Oral CR845 that is in Phase IIb clinical trial to treat moderate-to-severe acute and chronic pain, as well as in Phase I clinical trial to treat uremic pruritus; and CR701, which is in preclinical trial for the treatment of neuropathic and inflammatory pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845 for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845 in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading